Newron Pharmaceuticals S.p.A. (SWX:NWRN)
14.80
-0.28 (-1.86%)
Apr 29, 2026, 11:05 AM CET
Newron Pharmaceuticals Employees
Newron Pharmaceuticals had 27 employees as of December 31, 2025. The number of employees increased by 5 or 22.73% compared to the previous year.
Employees
27
Change (1Y)
5
Growth (1Y)
22.73%
Revenue / Employee
659.51K CHF
Profits / Employee
-456.51K CHF
Market Cap
313.75M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Santhera Pharmaceuticals Holding AG | 79 |
| BioVersys AG | 33 |
| Basilea Pharmaceutica AG | 189 |
| Xlife Sciences AG | 17 |
| Molecular Partners AG | 134 |
| Addex Therapeutics | 2 |
Newron Pharmaceuticals News
- 5 weeks ago - Newron Presents 2025 Financial Results and Provides 2026 Outlook - Business Wire
- 5 weeks ago - Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) - Business Wire
- 5 weeks ago - Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract - Business Wire
- 5 weeks ago - Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting - Business Wire
- 2 months ago - Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program - Business Wire
- 3 months ago - Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia - Business Wire
- 3 months ago - EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - Business Wire
- 4 months ago - Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent - Business Wire